Riskpilot← Back to searchSign inGet full accessMARMOZ Medicinkonsult AB
ABActiveOrg 5593176299Igelkottsvägen 49General medical practice activities · NACE 8621Est. 20210 employees
Revenue 2024
SEK 201K
-18% vs 2023
EBITDA margin
64.5%
-38% vs 2023
Equity ratio
65.7%
Financial strength
Net profit 2024
SEK 102K
-38% vs 2023
| Revenue | SEK 201K | -18% |
| EBITDA | SEK 130K | -38% |
| Net profit | SEK 102K | -38% |
| Total assets | SEK 387K | -17% |
| Equity | SEK 255K | -20% |
| Employees | 0 | — |
Legal name
MARMOZ Medicinkonsult AB
Org number
5593176299
Legal form
Aktiebolag
NACE code
8621 · General medical practice activities
Founded
17 maj 2021
Share capital
SEK 25 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget ska bedriva läkartjänster samt konsult- och utbildningsverksamhet inom hälso- och sjukvårdsbranschen samt därmed förenlig verksamhet.
Address
Igelkottsvägen 49
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Revenue | 53 | 169 | 247 | 201 |
| Staff expenses | — | — | — | −10 |
| EBITDA | 40 | 158 | 209 | 130 |
| Depreciation & amort. | −0 | — | — | — |
| EBIT | 40 | 158 | 209 | 130 |
| Net financials | — | −0 | 0 | −0 |
| Profit before tax | 40 | 120 | 209 | 129 |
| Tax | −9 | −25 | −43 | −27 |
| Net profit | 31 | 95 | 166 | 102 |
| Item | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
| Total assets | 81 | 253 | 467 | 387 |
| Equity | 56 | 152 | 317 | 255 |
| Long-term debt | 0 | — | — | — |
| Short-term debt | 25 | 63 | 112 | 95 |
| Total debt | 25 | 63 | 112 | 95 |
EBITDA margin
64.5%
This company
15.8%
Market median
+308% vs market
20212024
Equity ratio
65.7%
This company
38.2%
Market median
+72% vs market
20212024
Return on equity
40.3%
This company
18.4%
Market median
+119% vs market
20212024
Net profit margin
50.9%
This company
8.1%
Market median
+528% vs market
20212024
Asset turnover
0.52×
This company
1.12×
Market median
-54% vs market
20212024
Debt / equity
0.52×
This company
0.62×
Market median
+16% vs market
20212024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-05-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
MM Chief Executive Officer | Chief Executive Officer | 2022 |
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
| Deputy Board Member | 2022 | |
| Former (4) | ||
| Deputy Board Member | 2021 – 2022 | |
| Board of Directors | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
| Deputy Board Member | 2021 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of MARMOZ Medicinkonsult AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Marlene Marika Ellinor Mozart | Chief Executive Officer | 0 companies |
| Martin Alexander Björk | Deputy Board Member | 0 companies |
| Therese Anna Maria Bratteberg | Board of Directors | 0 companies |
| Bror Roine Ingemar Ankarström | Deputy Board Member | 0 companies |
| Matilda Margareta Bylund | Deputy Board Member | 0 companies |
| Per Olof Nylén | Deputy Board Member | 0 companies |